-
Study aim
-
The effect of selenium, vitamin C and methylprednisolone combination in mortality and morbidity of Covid-19 patients.
-
Design
-
A simple randomized, double-blind, placebo-controlled clinical trial
Clinical observers ,outcome assessors and data analysts are blind
-
Settings and conduct
-
Patients with Covid -19 admitted to the ICU of Sina Hospital in Tabriz will be included.Patients are randomly assigned to two groups. In the intervention group, a combination of selenium, vitamin C and methylprednisolone, and in the control group, only routine intensive care unit treatments based on the national protocol will be used to compare the effects of this combination in mortality and morbidity of acute respiratory distress syndrome caused by covid-19 in these patients. In this study, evaluator, and researcher are blinded to the study. Only the nurse or specialist providing the intervention (therapist) is aware of the study.
-
Participants/Inclusion and exclusion criteria
-
inclusion criteria:
Positive PCR test for Covid -19
Diffuse asymmetric pulmonary involvement on CT scan
Absence of evidence of liquid overload.
covid-19 ARDS due to berlin criteria
exclusion criteria:
Corticosteroid history in the past 3 months
Sensitivity to vitamin C.
Increased sensitivity to selenium.
Primary creatinine above 1.5.
Ethylene glycol poisoning.
-
Intervention groups
-
Intervention group: This group underwent routine treatments in the intensive care unit according to the national protocol for Covid 19 patients plus cocktail therapy of 1 mg daily intravenous selenium, 60 mg / kg / d vitamin C and 1 mg / kg / d one hour infusion of methylprednisolone for 7 days. And in the control group, only routine treatments of the intensive care unit will be provided according to the national protocol.
-
Main outcome variables
-
Days of hospitalization in ICU, mortality,duration of mechanical ventilation, days of hospitalization.